Recommendation of the President – Lamprene (clofazimine)
On 11 April 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 39/2025 on the validity of granting approval for reimbursement of the medicinal product Lamprene (clofazimine) for the indications: pulmonary mycobacteriosis, multidrug-resistant pulmonary tuberculosis